Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Published:2012-01 Issue:1 Volume:13 Page:25-32
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gianni Luca,Pienkowski Tadeusz,Im Young-Hyuck,Roman Laslo,Tseng Ling-Ming,Liu Mei-Ching,Lluch Ana,Staroslawska Elżbieta,de la Haba-Rodriguez Juan,Im Seock-Ah,Pedrini Jose Luiz,Poirier Brigitte,Morandi Paolo,Semiglazov Vladimir,Srimuninnimit Vichien,Bianchi Giulia,Szado Tania,Ratnayake Jayantha,Ross Graham,Valagussa Pinuccia

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

5. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available;Abramson;Clin Cancer Res,2011

Cited by 1922 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome;European Journal of Cancer;2024-11

3. Impact of Radiation Therapy Modalities on Loco-regional Control in Inflammatory Breast Cancer;International Journal of Radiation Oncology*Biology*Physics;2024-10

4. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

5. Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women;Cancers;2024-09-12